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Abstract:  
 
This paper explores place-specific factors that come together to enable firms and other kinds 
of organisation to produce new products, services and processes. The geography of the 
biomedical sector, that of clustering in particular regions, presents an opportunity for place-
specific understanding of processes involved in translational research in medical sciences, 
particularly with regard to the role of public policy and its outcomes in four bioscience 
regions in Europe. This might be in the way that public sector intervention can help actors in 
regions better to leverage resources to create synergy, or by building physical infrastructure 
leading to specific local pathways of translational research through which advances in 
healthcare are made. To explore these themes, the paper draws on data from a recently 
completed EU FP7 funded study (2010-2013) Healthcare Technology and Innovation for 
Economic Success (HealthTIES) of the ‘Healthcare Technology Innovation cycle’ in four 
bioscience regions: Medical Delta (Leiden, Rotterdam and Delft, Netherlands) Oxford and the 
Thames Valley, (UK), Biocat (Catalonia Spain) and Life Science Zurich (Switzerland) 
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1. Introduction 
A major area of research across disciplines is innovation geographies, that is place-specific 
factors that come together to enable firms and other kinds of organisation to produce new 
products, services and processes. As Feldman (2014) points out, while investments in 
innovation in certain places yield jobs, growth and prosperity, similar investments in others 
fail to produce the desired local effects. In this paper the focus is on innovation in the 
healthcare field at the local level through increased capacity-building in the form of 
infrastructures of different kinds and knowledge transfer programmes. Healthcare is defined 
broadly to incorporate life sciences and other sciences resulting in the development of 
diagnostic, therapeutic and convergent technologies.  
 
New areas of innovation, for example where new combinations of actors are required in order 
to support the value chain in a sector, often require policy experimentation to increase the 
effectiveness of the innovation process. Such experimentation is both facilitated by and 
results in geographic clusters of research and related activities as proximity facilitates 
different kinds of interaction (Cooke 2013). In the broader healthcare sector, research 
universities are often the central players in the geography of innovation - their research is 
funded through various government and non-government institutions, such as the National 
Institutes of Health in the United States, the Medical Research Council in the UK and under 
the Horizon2020 Programme
1
 in the European Union. 
 
 In the case of the UK, medical charities and private sector research laboratories are often co-
located with major research universities (Arbo and Benneworth 2007, Bagchi-Sen and 
Lawton Smith 2010) and hospitals. Medical charities are important funding sources. The link 
                                                          
1
 https://ec.europa.eu/programmes/horizon2020/en/h2020-section/nanotechnologies-advanced-materials-
advanced-manufacturing-and-processing-and (accessed November 18 2015) 
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among these various organizations provides the means through which the results of research 
are translated into commercializable technologies to benefit the end users – patients.  
 
This translational process is commonly known as “bench to bedside” research, that is, a 
system of taking laboratory discoveries to useful clinical applications and beyond through a 
translation process. Woolf (2008, 211) refers to translational research as the "effective 
translation of the new knowledge, mechanisms, and techniques generated by advances in 
basic science research into new approaches for prevention, diagnosis, and treatment of 
disease." In bioscience for example, the US has been the leader in translation research in the 
healthcare sector (Kenney 1986a and b, Bagchi-Sen et al. 2004).  In Europe such efforts are 
noticed in the UK, Germany (see for example Cooke 2004), and Switzerland (Gebhardt 
2015). Other countries (e.g. Israel, India) with strong science bases are yet to deliver effective 
support for this process (Breznitz 2013). 
 
While much of this translation occurs at the extra-territorial levels, local relationships and 
variations in the extent of local networks cannot be ignored (Lawton Smith and Bagchi-Sen 
2010, Casper 2013, Feldman 2014). Where they are effective, they facilitate the engagement 
between local stakeholders (e.g., entrepreneurs, intermediaries) who create the capacity (e.g., 
start ups, supplier networks) that sustain the development of the platform needed for 
translational research. The implication is that a university's success in translational or 
entrepreneurial activities depends on the quality of the regional environment around the 
university, that is the capacity of regional economies to support science and technology 
discoveries and their application (Casper 2013). Moreover, it is increasingly common for 
universities, one of the major stakeholders, to make internal adjustments to external 
conditions so that there is increased potential for translational research. Structural and 
procedural changes within universities (Oliver, 2004) have captured two institutional 
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“revolutions” in which such adjustments have been made. The first “institutional 
transformation” within universities opened the way to create new knowledge from academic 
research and collaboration. The second “institutional revolution“ made it possible to translate 
knowledge into commercial returns (Etzkowitz and Leydesdorff, 1998). Incentives put in 
place to create synergies between various organizations and individuals, resulted in 
collaborations for commercial opportunities, but not at the same rate or in the same form in 
different locations.  
 
The geography of the biomedical sector, that of clustering in particular regions, therefore 
presents an opportunity for place-specific understanding of processes involved in translational 
research in medical sciences, particularly with regard to the role of public policy and its 
outcomes. This might be in the way that public sector intervention can help actors in regions 
better to leverage resources to create synergy, or by building physical infrastructure leading to 
specific local pathways of translational research through which advances in healthcare are 
made.  
 
An obvious caveat is that of geographical scale. This paper discusses activity at the level of 
the region in four countries. ‘Regions’ are complex entities differing in scale; they are not 
only administrative entities but can be functional regions built for a particular purpose. To 
illustrate this we make two points. First, the EU’s own concept of ‘region’ is flexible. 
“Regions” are defined in the broader sense such as Länder, communities, autonomous 
communities, departments, provinces, counties, metropolitan regions and any other political 
entity with relevant competences to accomplish their engagements
2
. Second, our case study 
draws on data from a recently completed EU FP7 funded study (2010-2013) Healthcare 
                                                          
2
 http://cor.europa.eu/en/takepart/eer/Documents/EER_Leaflet_2013_EN.pdf 
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Technology and Innovation for Economic Success (HealthTIES) of the ‘Healthcare 
Technology Innovation cycle’ in four bioscience regions: Medical Delta (MD; Leiden, 
Rotterdam and Delft, Netherlands) Oxford and the Thames Valley, (OTV; UK), Biocat 
(Catalonia Spain) and Life Science Zurich (LSZ; Switzerland) along with an emerging region, 
Debrecen (Hungary)
3
.  Conceptually, the Healthcare Technology Innovation Cycle connects 
engineers and medical professionals, scientists and entrepreneurs, developers and end-users 
(medical doctors and patients). It specifies inputs into an innovation cycle (the science in the 
research base, research funding human capital), characteristics of innovation systems 
(technology transfer capacity building e.g. infrastructure and support for technology transfer) 
and outcomes such as the development of the biotech sector (new jobs, products and so on).  
 
The project investigated, in a benchmark comparison, a set of indicators which comprise 
innovation system parameters and best practices by region, an analysis of the scientific 
strengths at the universities and companies by region, together with a Strengths, 
Weaknesses/limitations, Opportunities and Threats (SWOT) analysis. The HealthTIES 
analysis is one of the first to undertake cross-national comparison by collecting data in a 
standardized way. The regions were chosen because all of them are leading national centres in 
the healthcare innovation value chain. However, these ‘regions’ vary in size, in the 
composition of their research and industrial bases, as well as in their administrative and 
functional status.  
 
We follow the HealthTIES framework to answer the following research question: What 
explains how translational research in the healthcare sector has developed in the four regions? 
Included in translational research is drug development, diagnostic businesses and other 
                                                          
3
 HealthTIES: Healthcare Technology and Innovation for Economic Success 
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therapies. It is argued that it is necessary to look beyond just universities and the biomedical 
sector to map the elements of different innovation systems (national, regional, sectoral and 
entrepreneurial ecosystem) within individual regions in order to account for their differing 
strengths, weaknesses and the prospects for their own healthcare technology innovation cycle.  
 
In order to contextualize the research question, we next review conceptualisations of different 
forms of innovation systems in order to highlight the impact of differences in structures and 
agency of individuals, organisations and policy-making (see Lundvall 2007, Autio et al., 
2014). These are then used as a basis for explaining the resulting patterns of activity. This is 
followed by the profile of each of the four major European bioregions: the methodology used 
to assess performance and then the data are examined. Finally, some conclusions are drawn 
on what has been learned about regional differences and the implications for prospects for 
future developments. 
 
2. Policy in systems approaches: implications for analysing translational 
research in healthcare at the local level 
 
Embedded in the analysis of what happens within individual regions with respect to 
translational research in healthcare are geo-historical innovation infrastructures and elements 
of different kinds of innovation systems. As Carlsson et al. (1999) point out, systems can be 
viewed in several dimensions including national (Lundvall 1992), regional (Cooke 1992, 
Cooke 1998) and sectoral (Malerba 2002, 2005). More recently the term ‘ecosystem’ 
(entrepreneurial, business and innovation) (Isenberg 2011, Feld 2013, see Spigel 2015 for a 
review) has been used to describe the interconnections of local actors for a common purpose, 
that is, supporting private sector-led economic development. In this paper, we are interested 
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both in technology transfer and in nested layers of policy, that is, the co-existence and 
interaction between policy intervention at national and regional/local scales. We consider how 
the science base and the agency of policy-making appear in each conceptualisation.  
 
We begin with the literature on national innovation systems (NIS) (Freeman 1995, Lundvall 
1988 & 1992, Nelson 1988 and 1993). This is because the scale of resources allocated by 
national governments in many countries to supporting the research base which includes 
universities from which translation science develops varies.  A key criticism of the NSI 
literature is that this ‘structuralist mode of explanation’ (Lundvall, 2007) means that 
individual-level agency and the micro-processes of entrepreneurial innovation have been 
largely overlooked (Autio et al, 2014). Indeed, ‘enterprise has become the forgotten element 
in the innovation systems story’ (Metcalfe and Ramlogan, 2008, Holden 2015).  
 
This criticism can equally be applied to how universities are treated in the NIS approach. 
Indeed, more recent developments have introduced agency by discussing how universities 
have broadened their scope to become entrepreneurial universities. These are noted for their 
societal role in creating wealth through making the applications commercializable and 
profitable (Etkzowitz 1983, Shane 2004, Wright et al., 2011).  
 
Closely tied to the concept of NIS are regional innovation systems (RIS) and sectoral 
innovation systems - both of which include knowledge infrastructures as the basic component 
for translational research (see Malerba 2002). Unlike NIS, however, these concepts are 
evolutionary having a focus on process/agency/change. 
 
The RIS concept (Cooke et al. 1992, 1998) focuses neither on technology nor on sectors but 
on the growth trajectories of regions taking into account broader industrial/sectoral, 
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institutional and research contexts. A RIS consists of “interacting knowledge generation and 
exploitation subsystems linked to global, national and other regional systems” that may 
stretch across several sectors in the regional economy (Asheim and Coenen 2005, 1174). 
Knowledge transfer mechanisms which account for clustering include contract research, 
formal R&D co-operations and forms of knowledge transmission that do not involve financial 
compensations for universities such as knowledge spillovers (through the provision of 
graduates to the local labour market) and informal contacts with firms.  
 
Universities in the RIS approach are important knowledge producers that may play bridging 
roles between themselves and the industrial world in the innovation-production spectrum at 
the regional level (Trippl et al. 2015). Perkmann et al. (2013) calls this ‘academic 
engagement’, bringing the agency of individual academics into play. Academic engagement 
represents an important way by which academic knowledge is transferred – or translated – 
into the industrial domain. Perkmann et al. show that the forms that it takes are related to the 
characteristics of individuals as well as the organisational and institutional contexts in which 
they work (see also Ankrah et al. 2013). Academic engagement is also related to innovation 
policy agenda (national, regional, local) on the translation or commercialisation of research.  
Therefore, the availability of knowledge and other resources in a region is associated with a 
concentration of firms, universities, research centres, and related innovation facilitating 
institutions and policy mechanisms. 
 
A sectoral system is a set of products and agents carrying out non-market and market 
interactions designed to bring products to market. Conceptually it is evolutionary with ‘its 
emphasis on dynamics, process and transformation’ (Malerba 2002, 249). It has a dominant 
knowledge base (although different mixes of them are found, for example in biotech, Todtling 
and Trippl, 2015), technologies, inputs and demand. It includes the science base as a source of 
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knowledge and inputs.  In the sectoral innovations concept, policy makers (central 
government and local authorities) appear as agents of change in the system alongside firms 
and non-firm organizations (such as universities or financial institutions), as well as 
organizations at lower (R&D department) or higher level of aggregation (e.g. firms’ 
consortia) and individuals (Malerba 2002) who are missing in the RIS concept. 
  
In both the sectoral and RIS approaches (Todtling and Trippl 2015) policy actors are agents 
whose interests lie in supporting capacity building for economic development in a locality 
(city, region) (Uyarra and Flanagan 2012).  As, Uyarra and Flanagan (2012) suggest, policies 
are also part of the system that they are trying to influence. As a consequence, past political 
decisions become part of the facilitating or constraining environment in which future 
decisions and action are made. However, as we show below, actors other than public policy 
makers have agency in de facto policy-making (Uyarra and Flangan 2012), that is, being 
involved a set of actions designed to target particular outcomes. Thus policy practice rather 
than being a coherent set of policy actions united by a vision is messy due to the co-existence 
of multiple stakeholders and interests. 
 
A recent version of an innovation systems approach with a focus on the local level is that of 
‘ecosystem’. Of the various versions, the entrepreneurial ecosystem approach is the most 
relevant to this discussion. An entrepreneurial ecosystem is ‘a set entrepreneurial actors, 
entrepreneurial organisations, and entrepreneurial processes …’ All of these, “connect, 
mediate and govern performance within the local entrepreneurial environment” (Mason and 
Brown 2013, 5). Here innovation is implicit but this concept is included because of the link 
Schumpeter (1911/1934) made between the entrepreneur and innovation.  
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The emphasis in the ecosystems approach is on cooperation, for example by public policy. 
Indeed, Feld (2012) while arguing that start-up communities, such as Boulder in the US, can 
be built up in any city is dismissive of the role of the state in stimulating entrepreneurial 
ecosystems. This allows other actors and organisations to be dominant in a local/regional 
environment, and also ties in with the notion of functional regions designed for a specific 
purpose. Spigel (2015) is clear that policy (economic policies and regulatory frameworks) and 
universities are both important pillars of an entrepreneurial ecosystem which combine social, 
political, economic and cultural elements within a region. 
 
However, it is most unlikely that all relevant actors will be engaged with others in an 
entrepreneurial ecosystem. For example, anchor firms (Feldman 2003, Agrawal and Cockburn 
2003), that is established firms who use a new technology, may create knowledge 
externalities that benefit smaller firms and increase overall innovative output in the region. 
They may not necessarily be engaged in an entrepreneurial ecosystem or in a sectoral or a 
RIS. Hence their direct articulated inputs may be missing. Again this last point highlights the 
role of individuals, particularly entrepreneurs, which Feldman (2014) describes as a missing 
element in the discussion of innovative places. As per the criticism of NIS approaches, 
Feldman argues that entrepreneurs are agents and are key to the creation of institutions and 
building of capacity that will sustain economic development. Hence, the role of policy-
making, if it appears at all is secondary to the agency of entrepreneurs.  
 
While we have defined each form of system, the analysis needs to take into account elements 
in each in order to provide a comprehensive understanding of the input, system and outputs. 
We have also suggested that there are limitations in the literature on innovation systems. For 
example, national institutions may facilitate or hinder supply and demand in the broader 
healthcare sector where innovation not just tied to the university laboratory but where a 
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sectoral innovation system needs hospitals for clinical tests and then needs firms for 
commercialization. This process is not linear but is constantly reinforcing with learning 
embedded in each and every feedback loop involving interactions between the different 
players (Kline and Rosenberg 1988, Rothwell 1994), particularly in this case entrepreneurs 
who are agents of change (Feldman 2014).  
 
At the regional level a number of factors (individual actions, organisational and institutional 
contexts and policy agenda) are significant in the extent and form that translational research 
occurs. Finally, the entrepreneurial ecosystem approach places the emphasis on the 
entrepreneur and the types of resources that they gain from being in an ecosystem (Spigel 
2015). Universities appear in all but one of these approaches as knowledge and human 
producers although as we suggest, there are limitations to the extent to which they do in 
practice engage in translational research. 
 
As we go through the analysis of inputs, systems and outputs, we identify where there are the 
gaps in policy and how policy might be able to help in the future to ensure that there is a 
better flow of inputs through a system to give outputs. Moreover, as we demonstrate, there 
has been policy experimentation in each country, with forms of intervention changing over 
time. 
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3. Study context: the four bioregions and policy 
 
3.1 National Contexts 
 
The four key bioscience regions of the ‘Healthcare Technology Innovation cycle’: Biocat, 
Medical Delta (MD) Oxfordshire and the Thames Valley (OTV) and Life Science Zurich 
(LSZ) are what Cooke (2004) has described as bioscience megacentres, albeit on a smaller 
scale than ones in the US such as Boston or San Francisco. Where they differ from each other 
is in the role of national governments in driving developments at the regional level, and the 
extent to which capacity building is locally based. For example two are regions, MD and LSZ, 
both created to promote translational medicine, with universities together with private sector 
engagement as a main driving force in economic development. In both, regional outcomes are 
related to NIS policies, while universities in Switzerland’s cantons also function within a RIS. 
In the Netherlands there are elements of sectoral innovation and entrepreneurial ecosystems. 
 
Spain has one of the ‘world’s leading centres of biotechnology research’ but lags behind in its 
technology transfer system and creation of new firms (Wharton 2014).
4
 While it has had a 
robust science base, it lacks strong entrepreneurial ecosystems, a bioscience sectoral 
innovation system and RIS. Its NIS is weakening when other countries are strengthening 
theirs. The Wharton Report finds that since the onset of the economic crisis, Spain has been 
losing its position in the world rankings of research and development activity. The sector has 
been especially hurt by cuts in public subsidies and the shortage of tax incentives for research, 
which translates for example into fewer patent registrations. Hence, the potential benefits 
                                                          
4
 http://knowledge.wharton.upenn.edu/article/spain-adopts-israel-model-engineer-biotech-
resurgence/(accessed November 26 2014) 
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from university-industry relationships in this and other sectors have not been realised (Garcia-
Aracil et al. 2015). This is because of comparatively weak policy efforts to incentivise 
knowledge and technology transfer compared to incentives to foster research. Spending on 
R&D (over half by firms) is concentrated in three main centres – Madrid, Catalonia and the 
Basque country, with Catalonia being one of the country’s national biotechnology hubs, with 
20% of all companies in the sector
5
. 
 
In the Netherlands, the government also ‘actively supported and co-funded a research and 
development infrastructure based on the concept of open innovation and long-term public–
private partnerships’ while investing in the strong research base6 7. These partnerships cover 
the entire life sciences value chain: they range from basic research to actual product and 
business creation. In cases where they address human health, they reach all the way from 
bench to bedside. They include all Dutch university medical centres, together with their 
associated universities.  
 
The UK has adopted a similar strategic approach to life sciences to that of the Netherlands but 
with the emphasis being on NIS as the driver rather than an RIS. According to the UK 
BioIndustry Association, the UK’s strength in life sciences lies in it having “4 of the top 10 
universities in the world, 19 of the top 100 universities, a stable of quality service providers, 
world class charitable supporters of the industry and a rich heritage of globally recognized 
medical research”8. In the UK, a major policy driver of the healthcare innovation cycle has 
                                                          
5
 http://www.biocat.cat/en/bioregion-facts-figures (accessed September 30 2015) 
6
 http://www.ibnetherlands.org/ (accessed November 26 2014) 
7
 http://www.hollandtrade.com/sector-information/life-sciences/netherlands.pdf (accessed September 30 
2015) 
8
 http://www.bioindustry.org/home/ (accessed November 26 2014) 
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been the government’s strategy for UK Life Sciences, introduced in 2011. It was designed to 
support companies through every stage of the product life cycle. This is of interest because it 
highlighted weaknesses in the UK healthcare innovation cycle for R&D funding for 
translational activities or the “translational funding gap”9. In spite of these weaknesses, the 
UK has one of the strongest biotech industries in Europe.  
 
In an attempt to improve translational medicine, the National Institute for Health Research 
(NIHR) has funded Biomedical Research Centers (BRCs). These are partnerships between 
universities and hospital trusts/foundations specifically for physician scientists to increase 
translational medicine – i.e. the NIHR is buying out their time to do more research with the 
intention of improving bench to bedside times. There are currently 11 BRCs (including 
Oxford) and major BRCs received around £100 million for 5 years in the second round which 
ends in 2016. However, funding is still dependent on academic output, possibly to a greater 
extent than ‘business’ potential.  
 
In Switzerland, the Federal Swiss government has not made direct investments in regional 
innovation and cluster policies. Instead the Federal budget for university-based education, 
research and innovation is very high. In addition Swiss cantons also fund universities and 
especially universities of applied sciences (Gebhardt 2015). Gebhardt argues that it is not 
necessary to use innovation policies as developmental measures in Switzerland as private 
investment is a key driving force. In the pharmaceutical sector, Switzerland, more renowned 
than the UK, is now leveraging that strength for broader biomedical sciences and the creation 
of its national biotech chain
10
.  
                                                          
9
 https://www.gov.uk/government/organisations/office-for-life-sciences (accessed June 7 2014) 
10
 http://www.swissbiotech.org/Php5/aa2/UserFiles/File/pdf/swissbiotechreport/SBR_2014.pdf accessed 
November 26 2014) 
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3.2 Regional Contexts 
 
Against this background on each of the four countries, the data in Tables 1, 2 and 3 in section 
4 are designed to show the particular inputs, system elements and outputs. These indicate 
what each possesses in the way of capacity for translation medicine. The regions, as we show 
below, differ in the sheer scale of activity, both geographically and in component elements. 
Key organizational differences lie in whether they exist as virtual, functional or 
administratively defined regions. The lead organizations and major players differ in each case 
and the relative balance of systemic elements (regional, sectoral, ecosystem) also varies.   
 
In the UK all areas have activity in the sector but the South East (Thames Valley, 
Oxfordshire), the East of England (Cambridgeshire) and London together contain 60% of all 
employment
11
. Entrepreneurs and small firms are key drivers of technological advancement in 
the biomedical sector, particularly in medical biotechnology. Many are young companies and 
are often spin-offs from universities (Cooke 2001, BIS 2013). In OTV, although the Thames 
Valley is included in some metrics, Oxford dominates. Reading University has only recently 
developed a science park and it does not have the excellence in biomedical sciences of Oxford 
University.  
 
There is a very strong focus on research: Oxford University’s translational trajectory is 
predicated on its very strong science base (a function of the NIS), much of it being funded by 
national and international research funding bodies (research councils, national charities, EU).  
                                                          
11
 https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/298819/bis-14-p90-
strength-opportunity-2013.pdf (accessed May 23 2014). 
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Where it differs from the other three regions is in its local entrepreneurial ecosystem This is 
indicated by the much smaller number of biotech companies than in the other three regions 
and by a lack of large firms. This is particularly distinctive indicating weaknesses in a 
biomedical sectoral system of innovation (Malerba 2002).   
 
Medical Delta was established in 2006 by the Delft University of Technology (TU Delft), 
Erasmus Medical Centre, Erasmus University, Leiden University and Leiden University 
Medical Center, and the City councils of Delft, Leiden and Rotterdam. MD is coordinated 
through its website
12
. Its aim was to realize breakthroughs in medical sciences and healthcare, 
to develop novel technologies and to fuel related economic opportunities through university-
industry linkages. MD is a medical technology cluster, home to a large number of biotech 
firms, with elements of both RIS (Cooke 1992, 1998) and an entrepreneurial ecosystem 
(Mason and Brown 2013, Spigel 2015) with stakeholders such as companies, business parks 
and local government.  
 
The Zurich life science cluster was established in 2001 by the University of Zurich and the 
Federal Institute of Technology Zurich (ETHZ), both in the Canton of Zurich. It aims to 
establish co-operation networks bringing together academia, industry and the public sector, 
and to support science education. Approximately 80% of the cluster activities are related to 
human health. In addition to the original tasks of promoting networking and communication 
within the universities and with the general public, two new networking platforms, the LSZ 
Young Scientist Network and the LSZ Business Network, have been initiated. 
 
                                                          
12
 http://www.medicaldelta.nl/ (accessed December 9 2014) 
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Biocat was established in 2006 by the Government of Catalonia and the Barcelona City 
Council. Its aim was to facilitate networking among biotech and pharma companies, research 
institutions/universities and an administration that fosters the biotechnological and biomedical 
sector in Catalonia (hence both features of a RIS and a sectoral innovation system are in 
place)
13
. Biocat is led by a biomedical network, the equivalent to Oxfordshire’s OBN (see 
below). Like OBN, it monitors what is happening in the sector in the region, but has more 
resources and plays a bigger role than OBN since it works closely with universities and 
hospitals.  
 
4. Data, Methodology, and Findings 
 
In this study we are using input, innovation system and output indicators to compare four 
leading bioscience regions. These indicators are also used as reflecting long term policy 
outcomes and/or organizational goals. However, this kind of analysis is fraught with 
methodological complexities owing to the difficulties in defining what is to be measured as 
indicators of performance, hence differences between places. For example, the EU’s (2011) 
Economic Performance Indicators (EPIs) for regional biotechnology are categorised under 
three dimensions: cluster dynamics, enablers, and outputs
14
. Differing assumptions about are 
used what is an input, what is an output and what are system elements. First, cluster dynamics 
includes the number of jobs created and the number of companies established (including 
growth and survival rates within the last three years). Second, cluster enablers here are 
designated as the external environment includes public funds raised, private funds raised; 
framework conditions; and the number of cluster organisations (cluster 
                                                          
13
 http://www.biocat.cat/en (accessed December 9 2014) 
14
 http://ec.europa.eu/research/bioeconomy/pdf/regional-biotech-report.pdf (accessed May 23 2014) 
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management/facilitator). Cluster outputs include revenue from marketed biotech 
products/technologies; revenue from licensing activities on biotechnology 
products/technologies, and numbers of newly developed and marketed biotechnology 
products/technologies.  
 
Other measures of outputs from universities include numbers of university products such as 
patents, licenses, and collaboration (Lendel 2010) which offer a range of possibilities to be 
absorbed by the local economy. They also include intangible as well as tangible and 
measurable outputs. Rossi and Rosli (2013) highlight the importance given to the 
measurement of the impact of knowledge transfer from universities via intellectual property 
rights and spin-offs. Measurement by geography and the impact of proximity are also 
important. Goldstein (2009) for example measures universities’ technology transfer by 
distance, types of research and kinds of universities. He finds spillovers from basic research to 
be less localised than those from applied research with spillovers from highly ranked research 
universities more geographically widespread – indicating the complexity of path development 
processes. 
 
Identifying outputs is problematic as studies do not necessarily agree as to what is an input or 
an output. For the biotech sector, standard output indicators include founding rates of firms, 
size (employment, turnover etc), specialization as indicated by new products, patents and 
drugs in development. Collectively these shape the specialization of a region from the private 
sector and universities (BIS 2013). 
 
In keeping with the suggested metrics above, the HealthTIES project developed a set of 
innovation indicators which were grouped into the three innovation phases: Input, Innovation 
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System and Output
15
 (Figure 1). Data were collected by teams by each of the partners. In 
three, Oxford, (Leiden, Rotterdam, Delft) and Zurich, the teams were academics working with 
local organizations, for example, in Biocat, data was collected by the Biocat team
16
. The 
criteria adopted for the study across the regions for innovation indicator datasets were that the 
data should be relevant for the HealthTIES disciplines - biotech, medtech, life sciences, 
engineering and medical sciences, and that it should discriminate between regional 
performances. This illustrates that within the healthcare sector, rather than there being just 
one dominant technology, a number of disciplines are involved (Todtling and Trippl 2015). 
The datasets needed to be quantitative in order to identify the impact of local expertise and 
conduct regional SWOT analyses. In this study the focus is on capacity building and 
exploitation of existing capacity, that is, the system and its inputs. In line with the caveats 
noted above, we accept that there are limitations to the chosen proxy variables.  However, at 
the current time, these are believed to be the best available. 
 
                                                          
15
 The innovation indicators, their weighting and scaling were derived as part of the HealthTIES project.  
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Figure 1. Inputs, Innovation Systems and Output in the Life Sciences  
(Source: http://vrr.healthties.eu/) 
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Regional information was collected on universities, research institutes, universities of applied 
sciences, intermediate vocational education, publications, care and cure providers, 
government, industry, technology transfer, science parks and incubators. Regional analyses, 
of trajectories were then performed and compared internally to the consortium and with 
clusters in other countries using a variety of statistical and graphical techniques
17
.  Next we 
show how the focus on life science based R&D, translational research, technology transfer 
and network development in each location has created place specific trajectories.  
 
4.1 Inputs 
 
Table 1 shows that the four regions are specialized in different areas of research and 
commercialization activities. For example, OTV is a leading region regarding its research 
activities and capabilities in the health related sectors rather than commercialization. An 
indicator of the region’s strength in knowledge is the number of professors with an H-index of 
30 and above
18
. MD, OTV and LSZ have at least a hundred more than Biocat. However, 
Oxford’s professors’ publication rates far exceed those in MD and LSZ. It is worth noting that 
other European countries do not have an equivalent of the Research Excellence Framework 
(REF), a system for assessing the quality of research in UK higher education institutions that 
drives academics to publish and obtain research funding
19
. This means that Oxford 
University’s academics are primarily focused on publications in order to maintain its global 
                                                          
17
 Data are available at http://vrr.healthties.eu/(accessed) June 3 2013) 
18
 The H-index is a measure which combines publication output and impact through the number of citations of 
an academic paper. 
19
 http://www.ref.ac.uk/ (accessed October 9 2015) 
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reputation. Therefore government policy (NIS) is a key driver of both institutional and the 
individual academic’s behavior. 
 
LSZ is ahead of OTV in the levels of external research funding. However, OTV does match 
that region in the number of ERC junior research grants but lags behind in the number of 
senior ERC grants. This might indicate on the one hand that the innovation cycle in OTV is in 
a comparatively early stage and is focused more on science than translational medicine than 
that of LSZ. The strength of the research base overall on the other hand illustrates that Oxford 
University and its teaching and medical research functions in local National Health Service 
hospitals, notably the John Radcliffe Hospital)
20
 primary position within the NIS (Freeman 
1988, Lundvall 1992).  
 
Moreover, MD, LSZ and Biocat outperform OTV in human capital particularly in the ability 
to attract more overseas as well as national MSc/PhD students. This suggests that a lack of 
skilled professionals might create bottlenecks for a growing industry, and is an indicator that 
OTV is different from the other regions.  It is not converging or diverging as it is falling 
behind in translational medicine given that it is less successful than the other regions in its 
research being commercialized i.e. that research and patents are not being translated into 
sufficient startups and spin-offs. Hence the agency of entrepreneurs in creating institutions 
and building capacity (Feldman 2014) within an entrepreneurial ecosystem (Spigel 2015) is 
stronger in MD, LSZ and Biocat than in OTV. 
 
Unlike in MD and LSZ, in OTV there is no local focus. Agency for change and underpinning 
of the translational process lies with national institutions. It should also be emphasized that 
                                                          
20
 http://www.ouh.nhs.uk/default.aspx (accessed 30 September 2015) 
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first rate academic basic research and publishing should not always be expected per se to 
found and develop new firms or applied projects. As Perkman et al. (2013) point out this is 
related to the characteristics of the individuals as well as their organizational and institutional 
contexts. 
 
Biocat is the strongest region for translational medicine overall with respect to the number of 
both research and general hospital beds and in the number of clinical trials. It also has more 
international PhD students and graduated MSc students, both national and international, 
suggesting that it has a younger profile than the other regions. This with its smaller number of 
professors with high H-indexes, lower levels of publications, research income and much 
smaller research infrastructure indicates that it is more of a teaching and applied research than 
a basis research region. In this respect there are potentially greater opportunities for agency at 
the local level to develop translational research activities given the high level of regional 
funding, building both RIS and entrepreneurial ecosystems. 
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Table 1: Inputs Indicators from HealthTIES 
Category Parameter Biocat Medical 
Delta 
Oxford & 
Thames 
Valley 
Life 
Science 
Zürich 
Knowledge Professors with an H-index 
>30 
125 245 238 231 
 Publications 2001-10 
 
798 1171 2264 1190 
Research 
funding 
Research Funding (Euro) 
 
450.69 463.23 632.99 1042.09 
Human 
Capital 
International. graduated 
MSc students 
949 331 148 348 
 International current PhD 
students 
1384 843 345 2762 
 National graduated MSc 
students 
5381 1266 193 1212 
 National current PhD 
students 
3742 1367 805 2167 
 Junior European Research 
Council grants 2007-10 
5 4 16 17 
 Senior European Research 
Council grants 2008-10 
6 9 19 33 
Infrastructure University area for research 
(m
2
) 
1147 77545 193353 315000 
 Beds in research hospitals 
 
5908 2096 1043 3366 
 Clinical trials phase I & II 
 
120 45 40 36 
Source: http://vrr.healthties.eu 
 
4.2 Innovation System 
The main features of the differences in the innovation systems relate to the size of the 
physical infrastructure (Table 2). For example, Biocat outperforms the other regions in the 
space on its science parks. Consistent with the evidence above, it has very much stronger 
institutional capacities in the form of technology transfer officers both on the science parks 
and in the universities. Not surprisingly it has the most spin-offs, but not that many more than 
MD. It does not have the same level of big public-private projects that are found in MD and 
OTV, countries where national policy is much stronger than in Spain. In Switzerland, private 
sector dominance may help to explain the lower number. 
 
However, while the OTV region has the next largest provision of space, its infrastructure for 
incubation of new and growing biotech firms is weak. SQW (2013) also identified a lack of 
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available premises inhibiting the location of Big Pharma in the county as well as and a lack of 
linkages between Oxford University and local firms. To address the lack of a biotech 
incubator, Oxford University has now started building a Bioescalator amongst other research 
institutes and next to the Churchill Hospital. Three other bioincubators are planned in 
Oxfordshire (part funded by national government, the private sector and in the case of the 
Bioescalator by Oxford University)
21
. This will improve the institutional environment for 
translational research (entrepreneurial ecosystem) but as yet, in policy terms, OTV does not 
yet have a RIS. By contrast, in MD, LSZ and Biocat there are elements of both RIS and 
entrepreneurial ecosystems.  
 
Table 2: Innovation System Indicators from HealthTIES 
Category Parameter Biocat Medical 
Delta 
Oxford & 
Thames 
Valley 
Life 
Science 
Zürich 
Innovation University Spin-Offs 2007-
10 
63 50 36 33 
 Granted US patents 2007-10 
 
50 54 50 40 
 Big public-private projects 
 
29 69 59 41 
Support TTO Full-time equivalents 
 
245 62.9 89 37.6 
 National governmental 
innovation (World 
Economic Forum Index 
2010-11) 
3.4 4.3 3.8 4.4 
Infrastructure National attractiveness 
(World Economic Forum 
Index 2010-11) 
4.49 5.33 5.25 5.63 
 Science parks area (m
2
) 
 
438920 1007500 312528 88700 
 Science parks support Full-
time equivalents 
181 22 49 17.75 
Source: http://vrr.healthties.eu 
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http://www.oxfordmail.co.uk/news/10969638.__67m_investment_into_four_science_hubs_in_Oxfordshire_fo
rms_main_part_of_three_part_Oxford_City_Deal___Audio/?ref=var_0 (accessed December 9 2014) 
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4.3 Outputs 
One of the major differences is in the commercial (translational) activity or outputs in the 
regions (Table 3). LSZ dominates the number of larger biotech companies, which has over 
twice those of MD. Surprising Biocat which has invested heavily in infrastructure, teaching 
and hospital beds is second only to LSZ on jobs in the biotech companies has the fewest 
larger firms, but its smaller firms employ nearly as many people.  
 
In spite of the strong research base in OTV, the number of biotech companies and 
subsequently the number of their FTEs is very low in comparison to the other regions. OTV’s 
employment in the biotech sector is half that of Biocat and somewhat over a third that of LSZ. 
It has a smaller number of biotech companies with less than 20 FTEs than other regions, 
particularly LSZ. OTV’s poor performance might indicate that despite the very strong 
scientific labour market, which is associated with high levels of entrepreneurship (Fritsch and  
Schindele 2011), the area lacks the people and the capabilities for supporting 
commercialization or fostering entrepreneurship, which seem to be present in all the more 
successful regions.  
 
OTV was able to attract throughout Europe the largest amount of investments between 2007 
and 2010 with 420.75 million Euro (followed by MD with 215.38). This indicates a perceived 
(scientific/economic) potential for further growth by investors and this has the potential to 
increase the output of the region over time. The small number of research hospital beds in the 
OTV region (Table 1) might hamper the benefits achieved through the interaction between 
research and patients and thus limit the experimental capacities. This is in spite of institutional 
capacity in the form of the clinical trials consortium.  
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Another prime indicator of translational research, from bench-to-bedside, is in the number of 
products on the market. Here LSZ scores most highly, followed by Biocat. This suggests that 
in Switzerland it is the private sector that is driving developments, a characteristic of the 
national innovation system, while in Biocat a government policy of collaboration is having an 
impact. However, OTV has the highest number of products in clinical trials, but is third 
highest in products at the discovery stage. This shows that there are no clear cut patterns to 
translational research across the board, rather there are indicators of where different kinds of 
agency are being felt in producing outcomes. 
 
Table 3: Output Indicators from HealthTIES  
Category Parameter Biocat Medical 
Delta 
Oxford & 
Thames 
Valley 
Life 
Science 
Zürich 
Jobs Biotech companies Full-
time equivalents 
29981 18636 13563 34440 
Companies Biotech companies with 
<20 Full-time equivalents 
338 195 154 1449 
 Biotech Companies with 
>20 Full-time equivalents 
16 108 46 262 
Deals Big Trade Sales 2001-10 
(>100 mio Euro) 
4 5 4 2 
Products Products on market 
 
207 138 122 282 
 Products clinical trials 
 
35 30 66 43 
 Products discovery phase 
 
72 55 49 37 
 Medicines available in 
countries EFPIA Patients’ 
W.A.I.T. Indicator Report 
2010 
36 54 n/a 37 
Capital Total investment 2007-10 
(>100 mio Euro) 
57.33 215.38 420.75 130.30 
 Number investments 2007-
10 (>100 mio Euro) 
13 11 20 16 
 Av. Series A investment 
2007-10 (>100 mio Euro) 
3.96 9.17 9.10 3.97 
Source: http://vrr.healthties.eu 
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While the data in the three tables indicate process outcomes, what they cannot show are direct 
outcomes in innovative bedside healthcare. Other indicators such as new therapy and health 
care structures, efficacy and effectiveness indexes could be more appropriately constructed as 
outcome indicators. These indicators should be seen as first step in indentifying national, 
regional and local conditions that underpin potential advances in healthcare and hence can be 
used to identify appropriate policy responses. 
 
5. Conclusions 
The paper considered inputs, the environment (innovation systems) and outputs in shaping  
clusters in the Healthcare sector in four leading locations in Europe. We are looking at data at 
one point in time to reflect upon the outcome of regional evolution to create a healthcare/life 
science sector that is at the forefront of translational research. The inputs tell us what they are 
working with, the innovation system also tell us what they are working with and how they are 
working, and the outputs provide indicators of the effectiveness of the translational research 
process in each.  We note how public policy and private sector involvement has produced 
distinctive characteristics either through enabling or not enabling processes needed for 
translational research. We have also used the concepts of NIS, RIS, sectoral innovation 
systems and entrepreneurial ecosystems to identify characteristics of developments in each 
location, highlighting that no one approach is sufficient to explain observed patterns of 
translational research.  
 
We show that with respect to ‘inputs’, the four regions are specialised in different areas of 
research and commercialization. OTV is clearly the odd one out. While the three other regions 
are converging in the inputs to support commercialization, OTV lags behind the others, 
especially Biocat, in the number of hospital beds and clinical trials, the later stages of the 
translational research process.  All three other regions have far higher student numbers, both 
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at Masters and PhD levels, i.e. the next generation of professionals and academics engaged in 
the translational research process. Biocat, however, is well behind the others in the 
availability of university infrastructure for research. MD and LSZ are similar to OTV in the 
number of highly published research professors but this does not translate into the same level 
of publications. LSZ is well ahead of the others with respect to research funding and 
associated university research areas for research, thus appears to be maintaining its high 
quality science base.  
 
In ‘innovation Systems’ Biocat is the leader of the four regions particularly for physical 
infrastructure, especially in full time TTO employees. It has more university spin-offs than 
the others but there is an imbalance between the resources devoted to commercialisation and 
extent (spin-offs and patents). Similarly the evidence suggests that OTV’s TTO resources are 
relatively inefficient as they have not resulted in as many university spin-offs as might be 
expected.  On other indicators, Biocat is behind the others on national attractiveness, and LSZ 
in science park capacity. A strength of MD’s sectoral innovation system is the number of big 
public-private projects that have a translational research element. 
 
It is ‘outputs’ where there is most obvious evidence of divergence across a range of 
indicators, indicating that the trajectory of each region in translational medicine is different. 
This is particularly the case with respect to the roles of entrepreneurs in driving innovation 
systems rather than being merely outputs. OTV in particular diverges from the other three 
regions in translational activity in the number of biotech companies, both smaller and larger.  
MD is the leading region in the number of companies, indicating an effective local 
entrepreneurial ecosystem (Mason and Brown 2013, Spigel 2015) but less so in the number of 
larger companies with more than 20 employees. Hence there are limitations to its overall 
sectoral innovation system (Malerba 2002, 2005) Here, LSZ is the most efficient in 
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generating the largest number of successful firms, as is also indicated by the number of 
products on the market. However, OTV has the highest number of products in clinical trials 
and total investments, suggesting that on this indicator, it has the potential to develop an 
effective translational research portfolio.  
 
The evidence suggests that it is systemic or innovation cycles where MD, LSZ and Biocat 
(but not OTV) are converging, but not necessarily through the same kinds of public policy 
intervention. Each shows elements of RIS and entrepreneurial ecosystems through their 
respective systems of governance through the interactions of organisations at the region level. 
What is striking is that OTV’s excellent science and technology base has not resulted in 
translational research that has resulted in high levels of entrepreneurship and growing biotech 
companies – it is massively behind LSZ and Biocat.  Overall it lags comparator regions in 
terms of a wide range of input, innovation system and output indicators, except in 
publications. As has been suggested above, the strength of the science base should not 
necessarily result in new firms and applied projects, even though a normative policy agenda 
suggest that it should. However, as OTV lacks the range of infrastructural support that is 
present in other regions such as incubators and technology transfer support, there is scope for 
public policy to identify how the local entrepreneurial ecosystem might be improved. 
 
The OTV HealthTIES innovation cycle appears to be limited by a lack of academic 
engagement (Perkmann et al. 2013) in translational research which is probably hampering its 
development. Instead, academics, as is the UK NIS, focus on publication. The comparatively 
low number of young academics graduating in OTV might result in bottlenecks for the 
growing biotech cluster but its current capacity to import is high as it is a very attractive 
region. A serious weakness is its apparent low capability to create spin-offs and to profit from 
its strong research as well as patent base. This might indicate insufficient capabilities 
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regarding the commercialization process or translation process as well as insufficient 
entrepreneurial education. An implication for policy is that, as nations move toward 
knowledge-based economic development, universities are a necessary but not sufficient 
condition for translational research to create profitable and societally valuable innovations.  
  
Research from the past two to three decades on the biotech sector (e.g. Cooke 2001, 2013, 
Stuart & Sorenson 2003, Kim et al. 2009) shows divergent trajectories or uneven 
development, that is certain universities have provided the pre-conditions to take off. Others 
which started late or have followed imitative strategies are going to take a longer time to 
adjust their internal strategies. This said, these universities are recognising that not all will 
follow the same path although the products are more or less the same (e.g., patents, licensing, 
spin offs). Thus a limitation to all of the approaches we have identified is how to build in 
evolutionary change, so that the different actors and organisations and combinations of both 
over time and influence translational research (see Spigel 2015 on entrepreneurial 
ecosystems). 
 
In a larger region, coordination among governance bodies may leverage these divergent paths, 
uneven knowledge base, and complex institutional capabilities to attain some bigger output at 
the end or realise synergies. In the UK various historical factors on one hand may add to the 
limitations, but on the other they provide the international reputation for science excellence 
that could potentially draw in international investment.  
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